Hepatocellular loss of mTOR aggravates tumor burden in nonalcoholic steatohepatitis-related HCC.
Kroh A, Walter J, Fragoulis A, Möckel D, Lammers T, Kiessling F, Andruszkow J, Preisinger C, Egbert M, Jiao L, Eickhoff RM, Heise D, Berndt N, Cramer T, Neumann UP, Egners A, Ulmer TF.
Kroh A, et al. Among authors: jiao l.
Neoplasia. 2023 Dec;46:100945. doi: 10.1016/j.neo.2023.100945. Epub 2023 Nov 15.
Neoplasia. 2023.
PMID: 37976569
Free PMC article.
However, mTOR inhibition failed to improve the outcome of HCC therapies, demonstrating the need for a better understanding of the molecular and functional consequences of mTOR blockade. We established a murine NASH-driven HCC model based on long-term western diet feeding c …
However, mTOR inhibition failed to improve the outcome of HCC therapies, demonstrating the need for a better understanding of the molecular …